# Cytoreductive Surgery(CRS) Plus Hyperthermic Intraperitoneal Chemotherapy(HIPEC) With Lobaplatin in Advanced and Recurrent Epithelial Ovarian Cancer

> **NCT03371693** · PHASE3 · UNKNOWN · sponsor: **Zhongnan Hospital** · enrollment: 112 (actual)

## Conditions studied

- Ovarian Cancer
- Ovary Neoplasm
- Ovarian Neoplasms
- Epithelial Ovarian Cancer
- Ovarian Cancer, Epithelial
- Hyperthermic Intraperitoneal Chemotherapy(HIPEC)

## Interventions

- **DEVICE:** HIPEC
- **DEVICE:** CRS
- **DEVICE:** IVCT

## Key facts

- **NCT ID:** NCT03371693
- **Lead sponsor:** Zhongnan Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2017-09-30
- **Primary completion:** 2022-12-30
- **Final completion:** 2023-03-30
- **Target enrollment:** 112 (ACTUAL)
- **Last updated:** 2020-05-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03371693

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03371693, "Cytoreductive Surgery(CRS) Plus Hyperthermic Intraperitoneal Chemotherapy(HIPEC) With Lobaplatin in Advanced and Recurrent Epithelial Ovarian Cancer". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT03371693. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*